SMC accepts dapagliflozin (ForxigaT) for restricted use in adults patients with type 2 diabetes mellitus
Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium has accepted dapagliflozin (ForxigaT) for restricted use within NHS Scotland in adults patients with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
The SMC states that dapagliflozin is restricted to use as dual therapy in combination with metformin, when metformin alone with diet and exercise does not provide adequate g...
Source: NeLM - Drug Specific Reviews - January 15, 2013 Category: Drugs & Pharmacology Source Type: news
